{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:17:48Z","timestamp":1785453468555,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T00:00:00Z","timestamp":1499817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003382","name":"Core Research for Evolutional Science and Technology","doi-asserted-by":"publisher","award":["19390302"],"award-info":[{"award-number":["19390302"]}],"id":[{"id":"10.13039\/501100003382","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Grant-in-Aid for Scientific Research","award":["21390330"],"award-info":[{"award-number":["21390330"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12888-017-1410-3","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T11:23:35Z","timestamp":1499858615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study"],"prefix":"10.1186","volume":"17","author":[{"given":"Kazuo","family":"Takiguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uezato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Itasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Narushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeo","family":"Kurumaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Tamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nakataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutoshi","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yasuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunimasa","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"issue":"2","key":"1410_CR1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.npp.1300313","volume":"29","author":"DC Javitt","year":"2004","unstructured":"Javitt DC, Balla A, Burch S, Suckow R, Xie S, Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor\/glycine-site agonists. Neuropsychopharmacology. 2004;29(2):300\u20137.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1410_CR2","first-page":"65","volume":"11","author":"T Nishikawa","year":"1991","unstructured":"Nishikawa T, Tanii Y, Umino A, Hashimoto A, Hata N, Takashima M, Shirayama Y, Takahashi K. Phencyclidine, NMDA receptor and schizophrenia. Yakubutsu Seishin Kodo. 1991;11(1):65\u20139.","journal-title":"Yakubutsu Seishin Kodo"},{"issue":"11","key":"1410_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"DC Javitt","year":"2004","unstructured":"Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984\u201397. 979","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1410_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.biopsych.2005.06.032","volume":"59","author":"GE Tsai","year":"2006","unstructured":"Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59(3):230\u20134.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1410_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0304-3940(89)90379-0","volume":"98","author":"WF Hood","year":"1989","unstructured":"Hood WF, Compton RP, Monahan JB. D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett. 1989;98(1):91\u20135.","journal-title":"Neurosci Lett"},{"issue":"8","key":"1410_CR6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","volume":"152","author":"DC Goff","year":"1995","unstructured":"Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995;152(8):1213\u20135.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"1410_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","volume":"153","author":"DC Goff","year":"1996","unstructured":"Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153(12):1628\u201330.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1410_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","volume":"45","author":"DC Goff","year":"1999","unstructured":"Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45(4):512\u20134.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1410_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","volume":"56","author":"DC Goff","year":"1999","unstructured":"Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21\u20137.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1410_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00213-004-2032-2","volume":"179","author":"DC Goff","year":"2005","unstructured":"Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology. 2005;179(1):144\u201350.","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"1410_CR11","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.schres.2008.08.012","volume":"106","author":"DC Goff","year":"2008","unstructured":"Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008;106(2\u20133):320\u20137.","journal-title":"Schizophr Res"},{"issue":"12","key":"1410_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0006-3223(96)00311-3","volume":"40","author":"BN van Berckel","year":"1996","unstructured":"van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40(12):1298\u2013300.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1410_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0893-133X(99)00014-7","volume":"21","author":"BN van Berckel","year":"1999","unstructured":"van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21(2):203\u201310.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1410_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1017\/S1461145798001242","volume":"1","author":"U Heresco-Levy","year":"1998","unstructured":"Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998;1(2):131\u20135.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"1410_CR15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1176\/appi.ajp.159.3.480","volume":"159","author":"U Heresco-Levy","year":"2002","unstructured":"Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159(3):480\u20132.","journal-title":"Am J Psychiatry"},{"issue":"1\u20132","key":"1410_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","volume":"56","author":"AE Evins","year":"2002","unstructured":"Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002;56(1\u20132):19\u201323.","journal-title":"Schizophr Res"},{"issue":"2","key":"1410_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF01276429","volume":"95","author":"NG Cascella","year":"1994","unstructured":"Cascella NG, Macciardi F, Cavallini C, Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm Gen Sect. 1994;95(2):105\u201311.","journal-title":"J Neural Transm Gen Sect"},{"issue":"5","key":"1410_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/00002826-199619050-00008","volume":"19","author":"RB Rosse","year":"1996","unstructured":"Rosse RB, Fay-McCarthy M, Kendrick K, Davis RE, Deutsch SI. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 1996;19(5):444\u201350.","journal-title":"Clin Neuropharmacol"},{"issue":"2\u20133","key":"1410_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.schres.2004.03.013","volume":"71","author":"EJ Duncan","year":"2004","unstructured":"Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71(2\u20133):239\u201348.","journal-title":"Schizophr Res"},{"issue":"10","key":"1410_CR20","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","volume":"164","author":"RW Buchanan","year":"2007","unstructured":"Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593\u2013602.","journal-title":"Am J Psychiatry"},{"issue":"1\u20133","key":"1410_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.schres.2016.03.035","volume":"174","author":"F Veru","year":"2016","unstructured":"Veru F, Jordan G, Joober R, Malla A, Iyer S. Adolescent vs. adult onset of a first episode psychosis: impact on remission of positive and negative symptoms. Schizophr Res. 2016;174(1\u20133):183\u20138.","journal-title":"Schizophr Res"},{"issue":"5","key":"1410_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1089\/cap.2015.0097","volume":"26","author":"M Stentebjerg-Olesen","year":"2016","unstructured":"Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P. Clinical characteristics and predictors of outcome of schizophrenia-Spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol. 2016;26(5):410\u201327.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"1410_CR23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.31887\/DCNS.2014.16.4\/pdazzan","volume":"16","author":"P Dazzan","year":"2014","unstructured":"Dazzan P. Neuroimaging biomarkers to predict treatment response in schizophrenia: the end of 30 years of solitude? Dialogues Clin Neurosci. 2014;16(4):491\u2013503.","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"1410_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.neuroimage.2006.02.024","volume":"31","author":"SM Smith","year":"2006","unstructured":"Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ, Matthews PM, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. NeuroImage. 2006;31(4):1487\u2013505.","journal-title":"NeuroImage"},{"key":"1410_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-244X-12-150","volume":"12","author":"L Clemmensen","year":"2012","unstructured":"Clemmensen L, Vernal DL, Steinhausen HC. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry. 2012;12:150.","journal-title":"BMC Psychiatry"},{"issue":"16","key":"1410_CR26","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1523\/JNEUROSCI.2450-14.2015","volume":"35","author":"A Takahashi","year":"2015","unstructured":"Takahashi A, Lee RX, Iwasato T, Itohara S, Arima H, Bettler B, Miczek KA, Koide T. Glutamate input in the dorsal raphe nucleus as a determinant of escalated aggression in male mice. J Neurosci. 2015;35(16):6452\u201363.","journal-title":"J Neurosci"},{"issue":"5","key":"1410_CR27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/138161210790361452","volume":"16","author":"GE Tsai","year":"2010","unstructured":"Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522\u201337.","journal-title":"Curr Pharm Des"},{"issue":"1\u20132","key":"1410_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0014-2999(94)90687-4","volume":"257","author":"D Quartermain","year":"1994","unstructured":"Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257(1\u20132):7\u201312.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1410_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.nlm.2005.01.001","volume":"83","author":"AS Parnas","year":"2005","unstructured":"Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83(3):224\u201331.","journal-title":"Neurobiol Learn Mem"},{"issue":"6929","key":"1410_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature01497","volume":"422","author":"Y Nong","year":"2003","unstructured":"Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, Salter MW. Glycine binding primes NMDA receptor internalization. Nature. 2003;422(6929):302\u20137.","journal-title":"Nature"},{"key":"1410_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.154","volume":"5","author":"A Uezato","year":"2015","unstructured":"Uezato A, Yamamoto N, Iwayama Y, Hiraoka S, Hiraaki E, Umino A, Haramo E, Umino M, Yoshikawa T, Nishikawa T. Reduced cortical expression of a newly identified splicing variant of the DLG1 gene in patients with early-onset schizophrenia. Transl Psychiatry. 2015;5:e654.","journal-title":"Transl Psychiatry"},{"issue":"8","key":"1410_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161406","volume":"11","author":"C Zhuo","year":"2016","unstructured":"Zhuo C, Liu M, Wang L, Tian H, Tang J. Diffusion tensor MR imaging evaluation of Callosal abnormalities in schizophrenia: a meta-analysis. PLoS One. 2016;11(8):e0161406.","journal-title":"PLoS One"},{"issue":"1\u20133","key":"1410_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.schres.2007.05.044","volume":"95","author":"H Fujiwara","year":"2007","unstructured":"Fujiwara H, Namiki C, Hirao K, Miyata J, Shimizu M, Fukuyama H, Sawamoto N, Hayashi T, Murai T. Anterior and posterior cingulum abnormalities and their association with psychopathology in schizophrenia: a diffusion tensor imaging study. Schizophr Res. 2007;95(1\u20133):215\u201322.","journal-title":"Schizophr Res"},{"key":"1410_CR34","doi-asserted-by":"crossref","unstructured":"Bopp MH, Zollner R, Jansen A, Dietsche B, Krug A, Kircher TT. White matter integrity and symptom dimensions of schizophrenia: a diffusion tensor imaging study. Schizophr Res. 2016;","DOI":"10.1016\/j.schres.2016.11.045"},{"key":"1410_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pscychresns.2016.01.011","volume":"248","author":"SJ Lee","year":"2016","unstructured":"Lee SJ, Kim B, Oh D, Kim MK, Kim KH, Bang SY, Choi TK, Lee SH. White matter alterations associated with suicide in patients with schizophrenia or schizophreniform disorder. Psychiatry Res. 2016;248:23\u20139.","journal-title":"Psychiatry Res"},{"issue":"1\u20133","key":"1410_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.schres.2008.03.008","volume":"103","author":"K Takei","year":"2008","unstructured":"Takei K, Yamasue H, Abe O, Yamada H, Inoue H, Suga M, Sekita K, Sasaki H, Rogers M, Aoki S, et al. Disrupted integrity of the fornix is associated with impaired memory organization in schizophrenia. Schizophr Res. 2008;103(1\u20133):52\u201361.","journal-title":"Schizophr Res"},{"issue":"3","key":"1410_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.pscychresns.2014.06.001","volume":"223","author":"E Ozcelik-Eroglu","year":"2014","unstructured":"Ozcelik-Eroglu E, Ertugrul A, Oguz KK, Has AC, Karahan S, Yazici MK. Effect of clozapine on white matter integrity in patients with schizophrenia: a diffusion tensor imaging study. Psychiatry Res. 2014;223(3):226\u201335.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1410_CR38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.pscychresns.2010.04.013","volume":"183","author":"D Mamah","year":"2010","unstructured":"Mamah D, Conturo TE, Harms MP, Akbudak E, Wang L, McMichael AR, Gado MH, Barch DM, Csernansky JG. Anterior thalamic radiation integrity in schizophrenia: a diffusion-tensor imaging study. Psychiatry Res. 2010;183(2):144\u201350.","journal-title":"Psychiatry Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-017-1410-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-017-1410-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T20:51:35Z","timestamp":1659214295000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-017-1410-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1186\/s12888-017-1410-3","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,12]]},"assertion":[{"value":"29 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed after approval by the Ethics Committee of each institution (Institutional Review Board of Tokyo Medical and Dental University Medical Hospital (No. 17\u201314), Research Ethics Committee of National Center of Neurology and Psychiatry (A2010\u2013013), Ethics Committee of Tokushima University Hospital (No. 1154\u20131), Institutional Review Board of Haryugaoka Hospital (No. 2), Ethics Committee of Ohmiya Kousei Hospital (No. 5)). Prior to study initiation, the study was sufficiently explained orally and using documents to all subjects and\/or their families and voluntary written consent was obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was included in the consent for study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"249"}}